BPI fold-containing family a member 2 as a biomarker of acute kidney injury—close but no (clinical) cigar?

Acute kidney injury (AKI) affects up to 50% of critically ill patients and is independently associated with both short and long-term mortality (1). Early identification of AKI is the main impulse for AKI biomarker research. Biomarkers are complementary to functional tests and, in addition, may be used to optimize AKI staging, to direct intervention, and to predict prognosis.